Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
11 Gennaio 2021 - 4:50PM
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the
“Company”), a clinical-stage biopharmaceutical company developing
products to improve the survival and/or quality of life for
patients who have unmet medical needs, announced today that
management will present at the H.C. Wainwright BIOCONNECT 2021
Virtual Conference.
The presentation is now available for on-demand
listening by visiting https://hcwevents.com/bioconnect/#. The press
release can also be viewed on our website at
https://processapharmaceuticals.com/investors-events.php.
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products
with existing clinical evidence of efficacy for patients with unmet
or underserved medical conditions who need treatment options that
improve survival and/or quality of life. The Company uses these
criteria for selection to further develop its pipeline programs to
achieve high-value milestones effectively and efficiently. Active
pipeline programs include: PCS6422 (metastatic colorectal cancer
and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and
PCS12852 (GI motility/gastroparesis). The members of the Processa
development team have been involved with more than 30 drug
approvals by the FDA (including drug products targeted to orphan
disease conditions) and more than 100 FDA meetings throughout their
careers. For more information, visit the company’s website
at www.ProcessaPharma.com.
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the registration
statement relating to the securities being sold in this offering,
which identifies important risk factors which could cause actual
results to differ from those contained in the forward-looking
statements.
For More Information: Michael Floyd
mfloyd@processapharma.com 301-651-4256
James Carbonara Hayden IR (646) 755-7412
james@haydenir.com
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Processa Pharmaceuticals (NASDAQ:PCSA)
Storico
Da Lug 2023 a Lug 2024